Companies › Amal Therapeutics
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ATP128 Self-adjuvanted chimeric recombinant protein vaccine targeting GP128 antigen | GP128 | Phase 1 | Colorectal Cancer | – |
| BI 754091 PD-1 inhibitor | PDCD1 | Phase 1 | Colorectal Cancer | – |
| VSV-GP128 Recombinant VSV expressing LCMV GP antigen for prime-boost vaccination | – | Phase 1 | Colorectal Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04046445 | ATP128 | Phase 1 | Colorectal Cancer | Oncology | May 2025 |
| NCT04046445 | BI 754091 | Phase 1 | Colorectal Cancer | Oncology | May 2025 |
| NCT04046445 | VSV-GP128 | Phase 1 | Colorectal Cancer | Oncology | May 2025 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.